US Edition
Published • loading... • Updated
Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer’s Story Finally Have a Second Act?
Mohit Bansal raised the price target to $250, saying late-stage immunology and kidney programs could offset declines in Alzheimer’s and MS sales.
Summary by 247wallst.com
2 Articles
2 Articles
Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer’s Story Finally Have a Second Act?
The post Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer’s Story Finally Have a Second Act? appeared first on 24/7 Wall St.. Quick Read Biogen (BIIB) stock received an upgrade from Wells Fargo to Overweight with a $250 price target from $200, driven by confidence in late-stage immunology and kidney pipeline programs as medium-term growth drivers beyond the company’s declining Alzheimer’s and MS franchises. Biogen’s revenue diver…
·New York, United States
Read Full Article
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
